MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/13696998.2025.2595885

Медицинская библиотека · Journal of medical economics · 2025

Association between elevations in alkaline phosphatase and healthcare utilization and costs among individuals with primary biliary cholangitis in the United States.

Gish Robert G, Mendler Michel H, Mena Edward A, Kim Chong, Murillo Perez C Fiorella, Pan Yi, Samnaliev Mihail, Ito Diane, Agapova Maria

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

Alkaline phosphatase (ALP) is a key biomarker in the management of primary biliary cholangitis (PBC). However, evidence of economic benefits of normal ALP is limited. We evaluated the relationship between ALP levels and healthcare resource utilization (HCRU) and costs among individuals with PBC in the United States.

METHODS

A retrospective analysis was conducted using Komodo's Healthcare Map insurance claims linked with laboratory data of individuals aged ≥18 years diagnosed with PBC between 09/01/2017 and 09/30/2023. At least two ALP tests ≥30 days apart were required, with the second designated as the index date. Continuous enrollment during the 12-month pre- and post-index periods was required. One-year regression-adjusted HCRU and healthcare costs (2024 US dollars) among individuals with persistently mildly elevated (ALP > 1 x upper limit of normal [ULN] ≤ 1.67 x ULN), elevated (ALP > 1.67 x ULN ≤3 x ULN) and highly elevated (ALP > 3 x ULN) were compared to those with persistently normal ALP (ALP ≤1 x ULN).

RESULTS

10,933 individuals with PBC were identified, including 9,544, 904, 297, and 248 with persistently normal, mildly elevated, elevated, and highly elevated ALP, respectively. Median age was 66 years, most were female (86.0%), White (58.2%), Medicare-insured (59.1%), and had ≥2 Charlson comorbidities (59.8%). Only 50.6% received PBC-specific treatment during baseline. Average 1-year healthcare costs were $18,747 (SD=$48,621). Compared to normal ALP, incremental regression-adjusted 1-year costs were $2,128 (p = 0.202), $10,289 (p < 0.001), and $12,229 (p < 0.001) for mildly, elevated, and highly elevated ALP, respectively.

CONCLUSION

Effectively treating PBC and lowering ALP may decrease healthcare costs.

Для цитирования: Gish Robert G, Mendler Michel H, Mena Edward A, Kim Chong, Murillo Perez C Fiorella, Pan Yi, Samnaliev Mihail, Ito Diane, Agapova Maria. Association between elevations in alkaline phosphatase and healthcare utilization and costs among individuals with primary biliary cholangitis in the United States.. Journal of medical economics. 2025. DOI: 10.1080/13696998.2025.2595885.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.